Dual Treatment of Suboptimal Doses of CsA and MSC Infusion Fully Prevents Acute Rejection in an Allogenic Model of Renal Transplantation.

L. de Ramon,¹ A. Merino,¹ E. Ripoll,¹ N. Bolaños,¹ M. Gomà,³ J. Cruzado,^1,2 J. Grinyó,^1,2 J. Torras.^1,2

¹Experimental Nephrology, IDIBELL-UB, Hospitalet Llobregat, Barcelona, Spain
²Nephrology, Hospital Universitari de Bellvitge, Hospitalet Llobregat, Barcelona, Spain
³Pathology, Hospital Universitari de Bellvitge, Hopitalet Llobregat, Barcelona, Spain

Meeting: 2017 American Transplant Congress

Abstract number: A43

Keywords: Graft survival, Rat, Rejection

Session Information

Session Name: Poster Session A: Cellular & Bone Marrow Transplantation Session I

Session Type: Poster Session

Date: Saturday, April 29, 2017

Session Time: 5:30pm-7:30pm

Presentation Time: 5:30pm-7:30pm

Location: Hall D1

The immunomodulatory characteristics of mesenchymal stem cells (MSCs) may lead to multifaceted strategies in rejection of organ transplantation. This study was designed to investigate the immunosuppressive effects of the donor-type MSCs infusion from Wistar rats to Lewis rats plus suboptimal doses of anti-calcineurinics in a renal transplantation model of Wistar to Lewis.

In this allogeneic kidney transplantation model, rats were randomly allocated into different groups: Non-Treated (n=10); Cyclosporine group (CsA) treated daily with 5mg/kg (n=9); CsA1/2 group was treated daily with 2.5mg/kg, a suboptimal therapeutic dosage (n=5); MSC group treated with two injections, at day -7 and day 0 (n=8) and MSC+CsA1/2 group which combines suboptimal CsA and Wistar MSC infusion (n=8). Heterotopic renal transplantation was performed Wistar to Lewis rats and the follow up was 21 days.

Graft function was assessed by serially measuring serum creatinine levels. At day 7, was when the creatinine picks maximum levels. MSC treated group displayed a significant reduction of creatinine values (3.5±2mg/dl) in contrast to Non-Treated group which showed 5±2mg/dl. Combining the sub-therapeutic dose of CsA with MSC, the reduction was greater (1.35±1.2mg/dl) and the values in the CsA1/2 (1.7±1.2mg/dl) group improved, reaching the CsA values (0.65±0.16mg/dl). We also saw differences in the mean survival time (MST), which was 12.4 days±4.2 in the Non-Treated group and it significantly increased in the MSC group up to 18.5 days±4.1. CsA1/2 showed 20±1.4 days of MST and, either CsA or CsA1/2+MSC groups have 100% of survival along the follow-up. Histological parameters paralleled functional data.

In conclusion, MSC infusion shows an immunomodulatory effect but dual therapy with MSC infusion and suboptimal doses of conventional immunosupressors offers a full immunological protection in the model of renal alotransplantation.

CITATION INFORMATION: de Ramon L, Merino A, Ripoll E, Bolaños N, Gomà M, Cruzado J, Grinyó J, Torras J. Dual Treatment of Suboptimal Doses of CsA and MSC Infusion Fully Prevents Acute Rejection in an Allogenic Model of Renal Transplantation. Am J Transplant. 2017;17 (suppl 3).

To cite this abstract in AMA style:

Ramon Lde, Merino A, Ripoll E, Bolaños N, Gomà M, Cruzado J, Grinyó J, Torras J. Dual Treatment of Suboptimal Doses of CsA and MSC Infusion Fully Prevents Acute Rejection in an Allogenic Model of Renal Transplantation. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/dual-treatment-of-suboptimal-doses-of-csa-and-msc-infusion-fully-prevents-acute-rejection-in-an-allogenic-model-of-renal-transplantation/. Accessed May 13, 2025.

« Back to 2017 American Transplant Congress